References
- Will BP, Berthelot J-M, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur. Cancer36, 724–735 (2000).
- •Thorough costing model describing lifetime costs associated with breast cancer by stage at diagnosis, useful reference for cost inputs and validation of cost-effectiveness models.
- Stockier M, Wilcken NRC, Ghersi D, John Simes R. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat. Rev 26,151–168 (2000).
- Haller DG, Fox KR, Schucter LM. Metastatic breast cancer. In: Breast Cancer Treatment: a Comprehensive Guide to Management. Fowble B, Goodman RL, Glick JH, Rosato EF (Eds). Mosby Year Book, MO, USA (1991).
- Simon MS, Ibrahim D, Newman L, Stan° M. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging19,453–463 (2002).
- Simpson D, Curran MP, Perry CM. Letrozole. A review of its use in postmenopausal women with breast cancer. Drugs64(11), 1213–1230 (2004).
- Tamaki Y, Miyoshi Y, Kim SJ, Tanji Y, Taguchi T, Noguchi S. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. Expert Rev Anticancer Ther. 3, 193–201 (2003).
- Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethamide in postmenopausal women with advanced breast cancer. Ann. Oncology9, 645 (1998).
- Jonat W Howell A, Bloqvist C et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidee) with MA in postmenopausal patients with advanced breast cancer. Eut: Cancer32A, 404–412 (1996).
- Dombernowsky P, Smith I, Falkson G et al Letrozole, a new aromatase inhibitor for advanced breast cancer. Double-blind randomised trial showing a dose effect and improved efficacy and tolerability comapred with megestrol acetate. J. Clin. Oncol 16,453–461 (1998).
- Buzdar AU, Jones SE, Vogel CL et al. A Phase III trial comparing anastrozole (1 and 10 mg), a potent and slective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma. Cancer 79,730–739 (1997).
- Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin. Cancer Res. 4,527–34 (1998).
- Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. j Surgical Oncol. 77,139–147 (2001).
- Mouridsen H, Gershanovich M, Sun Y. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a Phase DI study of the International Letrozole Breast Cancer Group. j Clin. Oncol. 19,2596-2606 (2001).
- •Pivotal trial describing the clinical effectiveness of letrozole as a first-line therapy for advanced breast cancer.
- Nabholtz JM, Buzdar AU, Pollak W et al Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. Clin. Oncol. 18,3758–3767 (2000).
- Nuijten M, Meester L, Waibel F, Wait S. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. PharmacoEconomics 16,379–397 (1999).
- Nuijten M, Fitzimon C, Wild E Economic evaluation of letrozole in the treatment of advanced breast cancer inpostmenopausal women in Canada. Value Health 3(1), 31–39 (2000).
- •• Comprehensive cost-effectiveness analysis of letrozole as a second-line therapy, using a detailed Markov model to describe patient pathways.
- Dranitsaris G, Leung PP, Mather J et al. Cost-utility analysis of second line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 11,591–601 (2000).
- Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91,484–489 (2001).
- Verma S, Rocchi A. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Cate Cancer11,728–734 (2003).
- ••Appealing methodology used to evaluateexemestane as a second-line therapy, model based primarily on patient-level data, which is used to good effect (analysis of anastrozole and letrozole is weaker).
- Karnon J, Jones T A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients. PharmacoEconomics21, 513–525 (2003).
- Karnon J, Johnston SRD, Jones T, Glendenning A. A trial-based economic evaluation of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal, advanced breast cancer. Ann. Oncol (2003).
- ••Simple methodology attaching cost andutility data to clinical estimates of effectiveness derived from patient-level data.
- Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer. Comparison of two aromatase inhibitors to tamoxifen. Am Clin. Oncol 26,289–296 (2003).
- Delea T, Smith R, Karnon J. Cost- effectiveness of letrozole versus tamoxifen as first-line hormonal therapy for postmenopausal women with advanced breast cancer: the US perspective. j Clin. Oncol. 542 (2002).
- Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. Clin. Oncol 17,3082–3090 (1999).
- Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91,484–489 (2001).
- Goss PE, Ingle JN, Martino S et al A randomised trial of letrozole in postmenoapusal women after 5 years of tamoxifen therapy for early-stage breast cancer. N. Engl. Merl 349 (19), 1793–1802 (2003).
- Karnon J, Johnston SRD, Delea T et al Cost-effectiveness of extended adjuvant letrozole after 5 years of tamoxifen in postmenopausal early breast cancer. ASCO (2004) (In Press).
Website
- Ferlay J, Bray F, Pisani P et al Globocan/ Eucan 2000: cancer incidence, mortality and prevalence worldwide. 16,2 (2004). www-dep.iarc.fr (Accessed July 2004)